SEC Form 4
AbCellera Biologics Inc. Common Shares (ABCL) insider trading
In the 12 months to Nov 15, 2026, 4 ABCL insiders reported open-market purchases of $3.5M across 11 filings; no open-market sales were filed.
Latest filing · Last 12 months · Source: SEC EDGAR · How we count
- Open-market sales
- $0
- 0 filings · 0 insiders
- Open-market purchases
- $3.5M
- 11 filings
Who traded ABCL, and when
- Purchase
ABCL daily close from Nov 17, 2025 to Nov 13, 2026, between $2.78 and $14.82, last $11.49. 0 sale and 11 purchase filings by 4 insiders, marked at their filing dates. Thermopylae Holdings Ltd., 10% owner: bought $1.4M across 3 filings, first filed Feb 27, 2026, last Nov 12, 2026. Michael R. Hayden, Director: bought $1.1M across 2 filings, first filed Aug 14, 2026, last Aug 24, 2026. Andrew Booth, Chief Financial Officer: bought $627.0K across 3 filings, first filed Feb 27, 2026, last Nov 13, 2026. John S. Montalbano, Director: bought $384.2K across 3 filings, first filed Nov 26, 2025, last Aug 18, 2026.
Largest mark · tap a row for others
Thermopylae Holdings Ltd. · 10% owner
Filing 1 of 2 within a week · $711,004 total
Purchase $580,284
177,457 shares at $3.27 avg
Filed Feb 27, 2026 · traded Feb 26
Close on filing date $3.61
Thermopylae Holdings Ltd. · 10% owner
10% owner
$1.4M boughtMichael R. Hayden · Director
Director
$1.1M boughtAndrew Booth · Chief Financial Officer
Chief Financial Officer
$627.0K boughtJohn S. Montalbano · Director
Director
$384.2K boughtOpen-market trades
11 filings in the last 12 months| Insider | Role | Sold | Bought | Filings | Pre-arranged (10b5-1) | Last filed |
|---|---|---|---|---|---|---|
| Thermopylae Holdings Ltd. | 10% owner | — | $1.4M | 3 | — | |
| Michael R. Hayden | Director | — | $1.1M | 2 | — | |
| Andrew Booth | Chief Financial Officer | — | $627.0K | 3 | — | |
| John S. Montalbano | Director | — | $384.2K | 3 | — |
| Filed | Insider | Type | Shares | Avg price | Value | Held after | Source |
|---|---|---|---|---|---|---|---|
traded | Andrew Booth Chief Financial Officer | Purchase | 8,600 | $11.33 | $97.4K | 491,400 | |
traded | Thermopylae Holdings Ltd. 10% owner | Purchase | 60,565 | $11.54 | $698.9K | 56,194,662 | |
traded | Michael R. Hayden Director | Purchase | 53,613 | $10.64 | $570.4K | 1,373,397 | |
traded | John S. Montalbano Director | Purchase | 10,000 | $11.03 | $110.3K | 251,000 | |
traded | Michael R. Hayden Director | Purchase | 46,387 | $10.37 | $481.0K | 1,319,784 | |
traded | Andrew Booth Chief Financial Officer | Purchase | 37,200 | $10.32 | $383.9K | 482,800 | |
traded | John S. Montalbano Director | Purchase | 20,000 | $4.77 | $95.4K | 241,000 | |
traded | Thermopylae Holdings Ltd. 10% owner | Purchase | 38,000 | $3.44 | $130.7K | 56,134,097 | |
traded | Andrew Booth Chief Financial Officer | Purchase | 42,600 | $3.42 | $145.7K | 195,600 | |
traded | Thermopylae Holdings Ltd. 10% owner | Purchase | 177,457 | $3.27 | $580.3K | 56,096,097 | |
traded | John S. Montalbano Director | Purchase | 50,000 | $3.57 | $178.5K | 221,000 |
GET /stocks/filings/vX/form-4?tickers=ABCL&filing_date.gte=2025-11-15&sort=filing_date.desc&limit=500{
"status": "OK",
"results": [
{
"tickers": [
"ABCL"
],
"issuer_cik": "0001703057",
"owner_cik": "0001834411",
"accession_number": "0001834411-26-000010",
"form_type": "4",
"filing_date": "2026-11-13",
"period_of_report": "2026-11-13",
"issuer_name": "AbCellera Biologics Inc.",
"issuer_trading_symbol": "ABCL",
"owner_name": "Booth Andrew",
"is_director": false,
"is_officer": true,
"is_ten_percent_owner": false,
"is_other": false,
"officer_title": "Chief Financial Officer",
"security_type": "non_derivative",
"record_type": "transaction",
"security_title": "Common Shares",
"transaction_timeliness": "E",
"aff_10b5_one": false,
"transaction_date": "2026-11-13",
"transaction_code": "P",
"equity_swap_involved": false,
"transaction_shares": 8600,
"transaction_price_per_share": 11.33,
"transaction_acquired_disposed": "A",
"shares_owned_following_transaction": 491400,
"transaction_value": 97438,
"not_subject_to_section_16": false,
"direct_or_indirect": "D"
},
{
"tickers": [
"ABCL"
],
"issuer_cik": "0001703057",
"owner_cik": "0001834449",
"accession_number": "0001834449-26-000009",
"form_type": "4",
"filing_date": "2026-11-12",
"period_of_report": "2026-11-12",
"issuer_name": "AbCellera Biologics Inc.",
"issuer_trading_symbol": "ABCL",
"owner_name": "Thermopylae Holdings Ltd.",
"is_director": false,
"is_officer": false,
"is_ten_percent_owner": true,
"is_other": false,
"security_type": "non_derivative",
"record_type": "transaction",
"security_title": "Common Shares",
"transaction_timeliness": "E",
"aff_10b5_one": false,
"transaction_date": "2026-11-12",
"transaction_code": "P",
"equity_swap_involved": false,
"transaction_shares": 60565,
"transaction_price_per_share": 11.54,
"transaction_acquired_disposed": "A",
"shares_owned_following_transaction": 56194662,
"transaction_value": 698920.1,
"not_subject_to_section_16": false,
"direct_or_indirect": "D",
"footnotes": [
{
"id": "F1",
"description": "The price reported in Column 4 is a weighted-average price. These shares were acquired in multiple transactions at prices ranging from $11.29 to $11.86. The reporting person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares acquired at each separate price within the range set forth in this footnote."
}
]
}
]
}
// trimmed to 2 resultsThe response includes every Form 4 record; this page keeps open-market purchases and sales on common stock and removes duplicate joint-filer rows.
Other insider activity (not market trades) · 4 records
- Option exercises1 record
- Gifts3 records
Reported on Form 4 but not purchases or sales in the market, so not counted in the totals above.
How to read this page
- Open-market purchase or sale
- A buy or sell of the company's stock at market price. Grants, option exercises, shares withheld for tax, gifts and employee stock plan purchases are listed separately and not counted.
- Filing date
- Insiders have two business days to report a trade. Totals and the chart use the filing date, when the trade became public.
Frequently asked questions
Has AbCellera Biologics Inc. Common Shares' CEO sold stock?
No. Carl L. G. Hansen (CEO) made no open-market sales filed as CEO in the last 12 months.
How current is ABCL’s insider data?
These are ABCL Form 4 filings from the last year, refreshed daily. The Massive Form 4 API has the full, continuously updated record.
What counts as an open-market buy or sell?
Only purchases and sales at the market price. Option exercises, grants, gifts, and shares withheld for taxes are reported on Form 4 but are left out of the buy and sell totals.
Build with AI
Track ABCL insider trades with your agent
This page joins two Massive endpoints: Form 4 filings and daily prices. Ask an agent to watch for new filings:
Using the Massive API (massive.com/docs/llms.txt), check Form 4 filings for ABCL every day with transaction_code=P and tell me when an insider files an open-market purchase, with their role, shares, price and the filing link.
Nothing on this page is investment advice. All data and content is provided for informational purposes under our Terms of Service.